AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00844103
- Locations
- 🇬🇧
Research Site, Macclesfield, Cheshire, United Kingdom
Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in France
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2011-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 275
- Registration Number
- NCT00842855
- Locations
- 🇫🇷
Research Site, Witry les Reims, France
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
Completed
- Conditions
- RefluxHeartburnRegurgitationEsophagitis
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2370
- Registration Number
- NCT00842387
- Locations
- 🇸🇪
Research Site, Vannas, Sweden
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00842556
- Locations
- 🇺🇸
Ppd Development, Austin, Texas, United States
Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 107
- Registration Number
- NCT00841048
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
Study to Investigate the Efficacy of Symbicort® SMART.
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2091
- Registration Number
- NCT00839800
- Locations
- 🇹🇭
Research Site, Khon Kaen, Thailand
Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: radioligand [18F]AZD4694Drug: radioligand [11C]AZD2184
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2009-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00838877
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00839683
- Locations
- 🇺🇸
Mds Pharma Services (Us) Inc., Neptune, New Jersey, United States
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00837967
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 743
- Registration Number
- NCT00837629